Tags: Drug.

Eritoran is an investigational drug for the treatment of severe sepsis an excessive inflammatory response to an infection. It is being developed by the Japanese pharmaceutical company Eisai Co. and administered intravenously as the sodium salt eritoran tetrasodium.In a phase III clinical trial eritoran did not perform better than existing treatments for the treatment of sepsis.

Eritoran_free_acid_skeletal.svg
ATC prefix
none
CAS number
185955-34-4
CAS supplemental
(tetrasodium salt)
FDA UNII code
551541VI0Y
IUPAC name
[(2R3R4R5S6R)-4-Decoxy-5-hydroxy-6-[[(2R3R4R5S6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-(Z)-octadec-11-enoyl]amino]-5-phosphonatooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] phosphoric acid
PubChem
6912404

Loading...

This page contains content from the copyrighted Wikipedia article "Eritoran"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.